6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Left B-OSE_Labeled_AE
Ventricular I-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
, O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neurotoxicity B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
drug O
reactions O
( O
frequency O
> O
25 O
% O
) O
with O
KADCYLA O
( O
n=884 O
treated O
patients O
) O
were O
fatigue O
, O
nausea O
, O
musculoskeletal O
pain O
, O
hemorrhage O
, O
thrombocytopenia O
, O
headache O
, O
increased O
transaminases O
, O
constipation O
and O
epistaxis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
clinical O
trials O
, O
KADCYLA O
has O
been O
evaluated O
as O
single-agent O
in O
884 O
patients O
with O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

The O
most O
common O
( O
frequency O
> O
= O
25 O
% O
) O
adverse O
drug O
reactions O
( O
ADRs O
) O
seen O
in O
884 O
patients O
treated O
with O
KADCYLA O
were O
fatigue B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
and O
epistaxis B-OSE_Labeled_AE
. O

The O
ADRs O
described O
in O
Table O
6 O
were O
identified O
in O
patients O
with O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
in O
a O
randomized O
trial O
( O
Study O
1 O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Patients O
were O
randomized O
to O
receive O
KADCYLA O
or O
lapatinib O
plus O
capecitabine O
. O

The O
median O
duration O
of O
study O
treatment O
was O
7.6 O
months O
for O
patients O
in O
the O
KADCYLA-treated O
group O
and O
5.5 O
months O
and O
5.3 O
months O
for O
patients O
treated O
with O
lapatinib O
and O
capecitabine O
, O
respectively O
. O

Two O
hundred O
and O
eleven O
( O
43.1 O
% O
) O
patients O
experienced O
> O
= O
Grade O
3 O
adverse O
events O
in O
the O
KADCYLA-treated O
group O
compared O
with O
289 O
( O
59.2 O
% O
) O
patients O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

Dose O
adjustments O
for O
KADCYLA O
were O
permitted O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Thirty-two O
patients O
( O
6.5 O
% O
) O
discontinued O
KADCYLA O
due O
to O
an O
adverse O
event O
, O
compared O
with O
41 O
patients O
( O
8.4 O
% O
) O
who O
discontinued O
lapatinib O
, O
and O
51 O
patients O
( O
10.5 O
% O
) O
who O
discontinued O
capecitabine O
due O
to O
an O
adverse O
event O
. O

The O
most O
common O
adverse O
events O
leading O
to O
KADCYLA O
withdrawal O
were O
thrombocytopenia B-OSE_Labeled_AE
and O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
. O

Eighty O
patients O
( O
16.3 O
% O
) O
treated O
with O
KADCYLA O
had O
adverse O
events O
leading O
to O
dose O
reductions O
. O

The O
most O
frequent O
adverse O
events O
leading O
to O
dose O
reduction O
of O
KADCYLA O
( O
in O
> O
= O
1 O
% O
of O
patients O
) O
included O
thrombocytopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Adverse O
events O
that O
led O
to O
dose O
delays O
occurred O
in O
116 O
( O
23.7 O
% O
) O
of O
KADCYLA O
treated O
patients O
. O

The O
most O
frequent O
adverse O
events O
leading O
to O
a O
dose O
delay O
of O
KADCYLA O
( O
in O
> O
= O
1 O
% O
of O
patients O
) O
were O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
and O
pyrexia B-OSE_Labeled_AE
. O

Table O
6 O
reports O
the O
ADRs O
that O
occurred O
in O
patients O
in O
the O
KADCYLA-treated O
group O
( O
n=490 O
) O
of O
the O
randomized O
trial O
( O
Study O
1 O
) O
. O

Selected O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
shown O
in O
Table O
7 O
. O

The O
most O
common O
ADRs O
seen O
with O
KADCYLA O
in O
the O
randomized O
trial O
( O
frequency O
> O
25 O
% O
) O
were O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
constipation B-OSE_Labeled_AE
. O

The O
most O
common O
NCI-CTCAE O
( O
version O
3 O
) O
> O
= O
Grade O
3 O
ADRs O
( O
frequency O
> O
2 O
% O
) O
were O
thrombocytopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

Table O
6 O
Summary O
of O
Adverse O
Drug O
Reactions O
Occurring O
in O
Patients O
on O
the O
KADCYLA O
Treatment O
Arm O
in O
the O
Randomized O
Trial O
( O
Study O
1 O
) O
Adverse O
Drug O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
KADCYLA O
( O
3.6 O
mg/kg O
) O
n=490Frequency O
rate O
% O
Lapatinib O
( O
1250 O
mg O
) O
+ O
Capecitabine O
( O
2000 O
mg/m O
2 O
) O
n=488Frequency O
rate O
% O
All O
grades O
( O
% O
) O
Grade O
3 O
- O
4 O
( O
% O
) O
All O
grades O
( O
% O
) O
Grade O
3 O
- O
4 O
( O
% O
) O
ND O
= O
Not O
determined O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
6.7 O
2.0 O
9.0 O
4.3 O
Anemia B-OSE_Labeled_AE
14.3 O
4.1 O
10.5 O
2.5 O
Thrombocytopenia B-OSE_Labeled_AE
31.2 O
14.5 O
3.3 O
0.4 O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
1.8 O
0.2 O
3.3 O
0.4 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Lacrimation B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3.3 O
0 O
2.5 O
0 O
Dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
3.9 O
0 O
3.1 O
0 O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
4.5 O
0 O
0.8 O
0 O
Conjunctivitis B-OSE_Labeled_AE
3.9 O
0 O
2.3 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspepsia B-OSE_Labeled_AE
9.2 O
0 O
11.5 O
0.4 O
Stomatitis B-OSE_Labeled_AE
14.1 O
0.2 O
32.6 O
2.5 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
16.7 O
0 O
4.9 O
0.2 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18.6 O
0.8 O
17.6 O
1.6 O
Vomiting B-OSE_Labeled_AE
19.2 O
0.8 O
29.9 O
4.5 O
Diarrhea B-OSE_Labeled_AE
24.1 O
1.6 O
79.7 O
20.7 O
Constipation B-OSE_Labeled_AE
26.5 O
0.4 O
11.1 O
0 O
Nausea B-OSE_Labeled_AE
39.8 O
0.8 O
45.1 O
2.5 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
7.1 O
0 O
8.2 O
0.2 O
Chills B-OSE_Labeled_AE
7.6 O
0 O
3.1 O
0 O
Pyrexia B-OSE_Labeled_AE
18.6 O
0.2 O
8.4 O
0.4 O
Asthenia B-OSE_Labeled_AE
17.8 O
0.4 O
17.6 O
1.6 O
Fatigue B-OSE_Labeled_AE
36.3 O
2.5 O
28.3 O
3.5 O
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
Nodular B-OSE_Labeled_AE
regenerative I-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
0.4 O
ND O
0 O
0 O
Portal B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
0.4 O
0.2 O
0 O
0 O
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
2.2 O
0 O
0.8 O
0 O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Procedural I-NonOSE_AE
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
1.4 O
0 O
0.2 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
9.4 O
0.6 O
3.9 O
0 O
Investigations B-NonOSE_AE
Blood B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
4.7 O
0.4 O
3.7 O
0.4 O
Increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
28.8 O
8.0 O
14.3 O
2.5 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypokalemia B-OSE_Labeled_AE
10.2 O
2.7 O
9.4 O
4.7 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
14.1 O
0.6 O
3.7 O
0 O
Arthralgia B-OSE_Labeled_AE
19.2 O
0.6 O
8.4 O
0 O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
36.1 O
1.8 O
30.5 O
1.4 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
8.0 O
0 O
4.1 O
0.2 O
Dizziness B-OSE_Labeled_AE
10.2 O
0.4 O
10.7 O
0.2 O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
21.2 O
2.2 O
13.5 O
0.2 O
Headache B-OSE_Labeled_AE
28.2 O
0.8 O
14.5 O
0.8 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
12.0 O
0.4 O
8.6 O
0.2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pneumonitis B-OSE_Labeled_AE
1.2 O
0 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
12.0 O
0.8 O
8.0 O
0.4 O
Cough B-OSE_Labeled_AE
18.2 O
0.2 O
13.1 O
0.2 O
Epistaxis B-OSE_Labeled_AE
22.5 O
0.2 O
8.4 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
5.5 O
0.2 O
9.2 O
0 O
Rash B-OSE_Labeled_AE
11.6 O
0 O
27.5 O
1.8 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hemorrhage B-OSE_Labeled_AE
32.2 O
1.8 O
16.4 O
0.8 O
Hypertension B-OSE_Labeled_AE
5.1 O
1.2 O
2.3 O
0.4 O
Table O
7 O
Selected O
Laboratory O
Abnormalities O
Parameter O
KADCYLA O
( O
3.6 O
mg/kg O
) O
Lapatinib O
( O
1250 O
mg O
) O
+ O
Capecitabine O
( O
2000 O
mg/m O
2 O
) O
All O
Grade O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grade O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Increased B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
17 O
< O
1 O
0 O
57 O
2 O
0 O
Increased B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
98 O
7 O
< O
1 O
65 O
3 O
0 O
Increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
82 O
5 O
< O
1 O
54 O
3 O
0 O
Decreased B-OSE_Labeled_AE
platelet I-OSE_Labeled_AE
count I-OSE_Labeled_AE
83 O
14 O
3 O
21 O
< O
1 O
< O
1 O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
60 O
4 O
1 O
64 O
3 O
< O
1 O
Decreased B-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
39 O
3 O
< O
1 O
38 O
6 O
2 O
Decreased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
33 O
3 O
0 O
31 O
6 O
< O
1 O
Hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
has O
been O
observed O
in O
two O
patients O
( O
0.2 O
% O
) O
with O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
clinical O
trials O
( O
n=884 O
) O
with O
KADCYLA O
as O
single-agent O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
the O
potential O
for O
an O
immune B-OSE_Labeled_AE
response I-OSE_Labeled_AE
to I-OSE_Labeled_AE
KADCYLA I-OSE_Labeled_AE
. O

A O
total O
of O
836 O
patients O
from O
six O
clinical O
studies O
were O
tested O
at O
multiple O
time O
points O
for O
anti B-NonOSE_AE
- I-NonOSE_AE
therapeutic I-NonOSE_AE
antibody I-NonOSE_AE
( I-NonOSE_AE
ATA I-NonOSE_AE
) O
responses O
to O
KADCYLA O
. O

Following O
KADCYLA O
dosing O
, O
5.3 O
% O
( O
44/836 O
) O
of O
patients O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
KADCYLA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
one O
or O
more O
post-dose O
time O
points O
. O

The O
presence O
of O
KADCYLA O
in O
patient O
serum O
at O
the O
time O
of O
ATA B-NonOSE_AE
sampling O
may O
interfere O
with O
the O
ability O
of O
this O
assay O
to O
detect O
anti B-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibodies I-NonOSE_AE
. O

As O
a O
result O
, O
data O
may O
not O
accurately O
reflect O
the O
true O
incidence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibody I-NonOSE_AE
development O
. O

In O
addition O
, O
neutralizing B-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibodies I-NonOSE_AE
has O
not O
been O
assessed O
. O

Immunogenicity B-NonOSE_AE
data O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
test O
methods O
used O
. O

Additionally O
, O
the O
observed O
incidence O
of O
a O
positive O
result O
in O
a O
test O
method O
may O
be O
influenced O
by O
several O
factors O
, O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
drug O
interference O
, O
concomitant O
medication O
and O
the O
underlying O
disease O
. O

Therefore O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
KADCYLA I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Clinical O
significance O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
yet O
known O
. O

